WO2008009857A3 - Modulateurs de la udp-glucose céramide glucosyltransférase dans le traitement de l'acné ou de l'hyperkératinisation - Google Patents

Modulateurs de la udp-glucose céramide glucosyltransférase dans le traitement de l'acné ou de l'hyperkératinisation Download PDF

Info

Publication number
WO2008009857A3
WO2008009857A3 PCT/FR2007/051684 FR2007051684W WO2008009857A3 WO 2008009857 A3 WO2008009857 A3 WO 2008009857A3 FR 2007051684 W FR2007051684 W FR 2007051684W WO 2008009857 A3 WO2008009857 A3 WO 2008009857A3
Authority
WO
WIPO (PCT)
Prior art keywords
acne
treatment
hyperkeratinization
udp
modulators
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/FR2007/051684
Other languages
English (en)
Other versions
WO2008009857A2 (fr
Inventor
Fernand Labrie
Van Luu-The
Ezequiel L Calvo
Irina Safonova
Michel Rivier
Isabelle Carlavan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galderma Research and Development SNC
Original Assignee
Galderma Research and Development SNC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galderma Research and Development SNC filed Critical Galderma Research and Development SNC
Priority to CA002656842A priority Critical patent/CA2656842A1/fr
Priority to EP07823603A priority patent/EP2046978A2/fr
Publication of WO2008009857A2 publication Critical patent/WO2008009857A2/fr
Publication of WO2008009857A3 publication Critical patent/WO2008009857A3/fr
Anticipated expiration legal-status Critical
Priority to US12/320,168 priority patent/US20100028878A1/en
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/91091—Glycosyltransferases (2.4)
    • G01N2333/91097—Hexosyltransferases (general) (2.4.1)
    • G01N2333/91102—Hexosyltransferases (general) (2.4.1) with definite EC number (2.4.1.-)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/20—Dermatological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention concerne une méthode in vitro de criblage de composés candidats pour le traitement préventif ou curatif de l'acné, comprenant la détermination de la capacité d'un composé à moduler l'expression ou l'activité de la UDP-glucose céramide glucosyltransférase (UGCG), ainsi que l'utilisation de modulateurs de l'expression ou de l'activité de cette enzyme pour le traitement de l'acné ou des désordres cutanés associés à une hyperkératinisation. L'invention concerne aussi des méthodes de diagnostic ou pronostic in vitro de ces pathologies.
PCT/FR2007/051684 2006-07-19 2007-07-18 Modulateurs de la udp-glucose céramide glucosyltransférase dans le traitement de l'acné ou de l'hyperkératinisation Ceased WO2008009857A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA002656842A CA2656842A1 (fr) 2006-07-19 2007-07-18 Modulateurs de la udp-glucose ceramide glucosyltransferase dans le traitement de l'acne ou de l'hyperkeratinisation
EP07823603A EP2046978A2 (fr) 2006-07-19 2007-07-18 Modulateurs de la udp-glucose céramide glucosyltransférase dans le traitement de l'acné ou de l'hyperkératinisation
US12/320,168 US20100028878A1 (en) 2006-07-19 2009-01-21 Modulators of UDP-glucose ceramide glucosyltransferase for treating acne or hyperkeratinization

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0653030 2006-07-19
FR0653030A FR2904001A1 (fr) 2006-07-19 2006-07-19 Modulateurs de la udp-glucose ceramide glucosyltransferase dans le traitement de l'acne ou de l'hyperkeratinisation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/320,168 Continuation US20100028878A1 (en) 2006-07-19 2009-01-21 Modulators of UDP-glucose ceramide glucosyltransferase for treating acne or hyperkeratinization

Publications (2)

Publication Number Publication Date
WO2008009857A2 WO2008009857A2 (fr) 2008-01-24
WO2008009857A3 true WO2008009857A3 (fr) 2008-04-24

Family

ID=37719181

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2007/051684 Ceased WO2008009857A2 (fr) 2006-07-19 2007-07-18 Modulateurs de la udp-glucose céramide glucosyltransférase dans le traitement de l'acné ou de l'hyperkératinisation

Country Status (5)

Country Link
US (1) US20100028878A1 (fr)
EP (1) EP2046978A2 (fr)
CA (1) CA2656842A1 (fr)
FR (1) FR2904001A1 (fr)
WO (1) WO2008009857A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2421184T3 (es) 2009-10-01 2013-08-29 Rhein Chemie Rheinau Gmbh Uso de aditivos de protección frente a la corrosión para la protección de aluminio y/o aleaciones de aluminio para procedimientos de acabado
US20140350049A1 (en) * 2011-11-29 2014-11-27 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for the treatment of darier disease
WO2019236722A1 (fr) * 2018-06-05 2019-12-12 Chatterjee Subroto B Inhibiteurs de synthèse de glycosphingolipides et méthodes d'utilisation
US20210386783A1 (en) * 2018-10-25 2021-12-16 School Corporation, Azabu Veterinary Medicine Educational Institution Use of glucosylceramide synthase gene-deficient t cell and therapeutic utilization thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002052270A2 (fr) * 2000-12-22 2002-07-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Methode permettant d'identifier des substances qui influencent positivement des affections inflammatoires de maladies chroniques inflammatoires des voies respiratoires
US20050049235A1 (en) * 2002-04-29 2005-03-03 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
US20050259483A1 (en) * 2002-09-30 2005-11-24 Oncotherapy Science, Inc. Genes and polypeptides relating to prostate cancers

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002052270A2 (fr) * 2000-12-22 2002-07-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Methode permettant d'identifier des substances qui influencent positivement des affections inflammatoires de maladies chroniques inflammatoires des voies respiratoires
US20050049235A1 (en) * 2002-04-29 2005-03-03 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
US20050259483A1 (en) * 2002-09-30 2005-11-24 Oncotherapy Science, Inc. Genes and polypeptides relating to prostate cancers

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
CHEMISTRY AND PHYSICS OF LIPIDS, vol. 143, no. 1-2, September 2006 (2006-09-01), 47TH INTERNATIONAL CONFERENCE ON BIOSCIENCE OF LIPIDS; PECS, HUNGARY; SEPTEMBER 05 -10, 2006, pages 68, ISSN: 0009-3084 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1996, SANDO G. ET AL.: "Retinoic acid suppresses glucosylceramide formation in cultured human keratinocytes", XP009078992, Database accession no. PREV199698804821 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; April 1999 (1999-04-01), MADISON K. ET AL.: "A specific inhibitor of ceramide glucosyltransferase alters lamellar granule assembly in cultured human keratinocytes", XP009079001, Database accession no. PREV199900228013 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; April 1999 (1999-04-01), SANDO G. ET AL.: "Ceramide glucosyltransferase expression is regulated by protein kinase C in cultured human keratinocytes", XP009079003, Database accession no. PREV199900226802 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; March 2004 (2004-03-01), SANDO G. ET AL.: "Ceramide glucosyltransferase expression is regulated by a MAPK pathway involving non-classical PKC isoforms, PI3K, MEK1/2, and ERK", XP009078998, Database accession no. PREV200510114425 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; September 2006 (2006-09-01), THIEME F. ET AL.: "Effects of exogenously administered sphingolipid derivatives on keratinocyte lipid metabolism using a combination of lipid profiling and gene expression analysis", XP009079009, Database accession no. PREV200600653185 *
JOURNAL OF INVESTIGATIVE DERMATOLOGY, vol. 106, no. 4, 1996, ANNUAL MEETING OF THE SOCIETY FOR INVESTIGATIVE DERMATOLOGY; WASHINGTON, D.C., USA; MAY 1-5, 1996, pages 916, ISSN: 0022-202X *
JOURNAL OF INVESTIGATIVE DERMATOLOGY, vol. 112, no. 4, April 1999 (1999-04-01), 60TH ANNUAL MEETING OF THE SOCIETY FOR INVESTIGATIVE DERMATOLOGY; CHICAGO, ILLINOIS, USA; MAY 5-9, 1999, pages 542, ISSN: 0022-202X *
JOURNAL OF INVESTIGATIVE DERMATOLOGY, vol. 112, no. 4, April 1999 (1999-04-01), 60TH ANNUAL MEETING OF THE SOCIETY FOR INVESTIGATIVE DERMATOLOGY; CHICAGO, ILLINOIS, USA; MAY 5-9, 1999, pages 543, ISSN: 0022-202X *
JOURNAL OF INVESTIGATIVE DERMATOLOGY, vol. 122, no. 3, March 2004 (2004-03-01), 65TH ANNUAL MEETING OF THE SOCIETY-FOR-INVESTIGATIVE-DERMATOLOGY; PROVIDENCE, RI, USA; APRIL 28 -MAY 01, 2004, pages A79, ISSN: 0022-202X *

Also Published As

Publication number Publication date
FR2904001A1 (fr) 2008-01-25
CA2656842A1 (fr) 2008-01-24
US20100028878A1 (en) 2010-02-04
EP2046978A2 (fr) 2009-04-15
WO2008009857A2 (fr) 2008-01-24

Similar Documents

Publication Publication Date Title
WO2007067968A3 (fr) Effets d'inhibiteurs de fgfr3 sur la transcription genetique
WO2007114901A3 (fr) Procede de diagnostic de l'adhd (trouble de l'hyperactivite avec deficit de l'attention) et des troubles comportementaux apparentes
WO2009048072A1 (fr) ANTICORPS CIBLANT LA PROTÉINE Siglec-15 LIÉE AUX OSTÉOCLASTES
EP2068913A4 (fr) Immunomodulateurs, preparations et compositions comprenant ces immunomodulateurs, tests pour evaluer l'activite de ces immunomodulateurs ainsi que les preparations et les compositions les comprenant, et methodes associees
ATE511645T1 (de) Testverfahren zum nachweis von antikörpern gegen lysosomenenzyme
WO2009124330A3 (fr) Traitement de maladies tumorales
IL185998A0 (en) Methods for diagnosis and treatment of processing difficulties, integration problems, imbalances and abnormal postures
WO2007114986A3 (fr) Sondes coopératives et leurs procédés d'utilisation
WO2009087462A3 (fr) Récepteur à éphrine de type a
WO2008009856A3 (fr) Modulateurs de hsd17b7 dans le traitement de l'acné ou de l'hyperséborrhée
WO2008020765A3 (fr) Milieu d'imagerie comprenant du lactate et du pyruvate 13c hyperpolarisé
WO2005074985A3 (fr) Methodes de modulation de cd200
WO2008009857A3 (fr) Modulateurs de la udp-glucose céramide glucosyltransférase dans le traitement de l'acné ou de l'hyperkératinisation
WO2008009855A3 (fr) Modulateurs de sc4mol dans le traitement de l'acné ou de l'hyperséborrhée
WO2007101063A3 (fr) Traitement de troubles liés au développement
WO2008009859A3 (fr) Modulateurs de scarb-1 dans le traitement de l'acné ou de l'hyperséborrhée
WO2008009854A3 (fr) Modulateurs du transporteur abcd3 dans le traitement de l'acné ou de l'hyperséborrhée
WO2008115710A3 (fr) Biomarqueurs pour le cancer
WO2008070552A3 (fr) Inhibiteurs de la protéine tyrosine phosphatase permettant de favoriser l'hypertrophie cardiaque physiologique
WO2008027379A3 (fr) Indicateurs d'activité sirtuine et procédés d'utilisation de ceux-ci
WO2009017719A8 (fr) Modulateurs du récepteur ccr9 et leurs procédés d'utilisation
WO2008009858A3 (fr) Modulateurs de elovl5 dans le traitement de l'acné ou de l'hyperséborrhée
WO2007083287A3 (fr) Procédé d'essai permettant d'évaluer l'irritation de la peau
WO2008012692A3 (fr) Test d'efficacité des inhibiteurs d'histone déacétylase
WO2008009852A3 (fr) Modulateurs de la lanostérol synthétase dans le traitement de l'acné ou de l'hyperséborrhée

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07823603

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2007823603

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2656842

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU